Pharmaceuticals 28 November 2025 - 3 December 2025

Eli Lilly shares traded near $1,060 midday December 2, just below record highs, after a year of sharp gains fueled by obesity and diabetes drugs. The company cut U.S. self-pay prices for Zepbound on December 1, following a federal deal to lower GLP-1 prices. Lilly’s market cap briefly topped $1 trillion in November, the first for a healthcare firm. WHO issued its first guideline recommending GLP-1 drugs for obesity on December 1.

Eli Lilly shares closed at $1,075.47 on Friday, down 2.6% after a month-long rally that briefly pushed its market value above $1 trillion. The stock remains up about 39% year-to-date and surged roughly 26–31% in November, driven by demand for its obesity drugs. Investors are weighing recent policy headlines and valuation concerns ahead of Monday’s open. No pre-market quote was available with US markets closed over the weekend.

Eli Lilly closed Friday at $1,075 per share, capping a November surge that pushed its market value above $1 trillion—the first for a pharmaceutical company. Shares rose about 26% in November and are up over 40% in 2025. Investors are debating whether the stock, trading at a trailing P/E of 70, can sustain further gains amid strong demand for its GLP-1 obesity drugs.

Eli Lilly shares closed at $1,075.47 on November 28, down 2.6%, pulling the S&P 500 healthcare sector lower despite gains in the broader market. The stock remains up over 30% for November and more than 40% year-to-date, with a market cap around $1 trillion. JPMorgan raised its price target to $1,150. Recent gains followed strong Q3 earnings and surging sales of Mounjaro and Zepbound.